Clinical and laboratory profiles of the SARS-CoV-2 Delta variant compared with pre-Delta variants

•Clinical characteristics differed between the Delta and pre-Delta variant in hospitalized cases.•Patients with Delta-like characteristics have higher inflammatory markers.•The gradient boosting model may identify patients with Delta-like characteristics.•This approach may address real-world challen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases 2022-07, Vol.120, p.88-95
Hauptverfasser: Bhakta, Shivang, Sanghavi, Devang K., Johnson, Patrick W., Kunze, Katie L., Neville, Matthew R., Wadei, Hani M., Bosch, Wendelyn, Carter, Rickey E., Shah, Sadia Z., Pollock, Benjamin D., Oman, Sven P., Speicher, Leigh, Siegel, Jason, Libertin, Claudia R., Matson, Mark W., Moreno Franco, Pablo, Cowart, Jennifer B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Clinical characteristics differed between the Delta and pre-Delta variant in hospitalized cases.•Patients with Delta-like characteristics have higher inflammatory markers.•The gradient boosting model may identify patients with Delta-like characteristics.•This approach may address real-world challenges of variant sequencing. The emergence of SARS-CoV-2 variants of concern has led to significant phenotypical changes in transmissibility, virulence, and public health measures. Our study used clinical data to compare characteristics between a Delta variant wave and a pre-Delta variant wave of hospitalized patients. This single-center retrospective study defined a wave as an increasing number of COVID-19 hospitalizations, which peaked and later decreased. Data from the United States Department of Health and Human Services were used to identify the waves’ primary variant. Wave 1 (August 8, 2020–April 1, 2021) was characterized by heterogeneous variants, whereas Wave 2 (June 26, 2021–October 18, 2021) was predominantly the Delta variant. Descriptive statistics, regression techniques, and machine learning approaches supported the comparisons between waves. From the cohort (N = 1318), Wave 2 patients (n = 665) were more likely to be younger, have fewer comorbidities, require more care in the intensive care unit, and show an inflammatory profile with higher C-reactive protein, lactate dehydrogenase, ferritin, fibrinogen, prothrombin time, activated thromboplastin time, and international normalized ratio compared with Wave 1 patients (n = 653). The gradient boosting model showed an area under the receiver operating characteristic curve of 0.854 (sensitivity 86.4%; specificity 61.5%; positive predictive value 73.8%; negative predictive value 78.3%). Clinical and laboratory characteristics can be used to estimate the COVID-19 variant regardless of genomic testing availability. This finding has implications for variant-driven treatment protocols and further research.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2022.04.050